Quintiles Recieves Phase II/III Clinical Research Industry Accolade
News May 22, 2013
Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013 CRO Quality Benchmarking Report – Phase II/III. Respondents also rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again.
“We are deeply committed to helping our customers increase their probability of success at every stage of the product lifecycle,” said Paula Brown Stafford, President, Clinical Development at Quintiles. “We are delighted to see that our leadership and commitment to both quality and customer satisfaction are recognized by the industry.”
According to the report:
• Quintiles is the best Phase II/III clinical research service provider at differentiation based on service quality;
• Quintiles leads large CROs in customer loyalty and is the most cited industry leader;
• Quintiles most consistently meets customer expectations, and is the leader among large CROs in exceeding expectations for global reach, breadth of services, local regulatory knowledge, commercial market knowledge and the ability to consistently meet “First Patient In” timelines.
Survey respondents also recognized Quintiles as a leader among large CROs for meeting customer expectations for real-time access to data. Quintiles is committed to transforming drug development through its data and proprietary knowledge engine, Quintiles Infosario®, an innovative solution that seamlessly integrates data, Quintiles’ systems, processes and therapeutic expertise to help customers make faster, more informed decisions.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE